Summary
The absolute bioavailability (f) of pirenzepine was determined in 27 intensive care patients receiving the drug for prophylaxis and therapy of upper gastrointestinal tract bleeding. A multiple oral and intravenous dosage regimen and the times of blood sampling were adapted to individual conditions and treatment.
Mean fin the patients was 0.28, which was significantly higher than in 12 normal subjects (0.14). It showed no dependence on age (range 20–82 y), nor on the risk factors cardiac insufficiency, renal and hepatic dysfunction, gastrectomy (Billroth II) and bleeding gastrointestinal ulcers, nor on concomitant administration of metoclopramide or antacids.
Due to the wide therapeutic index of pirenzepine, it is concluded that individualization of therapy is not necessary for patients in intensive care.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schuster DP, Rowley H, Feinstein S, McGue MK, Zuckerman GR (1984) Prospective evaluation of the rsik of upper gastrointestinal bleeding after admission to a medical intensive care unit. Am J Med 76: 623–30
Carmine AA, Brogden RN (1985) Pirenzepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs 30: 85–126
Klein HJ (1984) Gastrointestinal complications in neurosurgical patients — a common but causally treatable phenomenon. Abstract, Symposium on pirenzepine, new aspects in research and therapy. Excerpta Medica, Amsterdam, p 26
Tryba M (1987) Zusammenfassende Bewertung und klinische Empfehlungen zur medikamentösen Stressblutungsprophylaxe unter Berücksichtigung von Kosten, Handhabung und Compliance. In: Tryba M (ed) Rationale Stressblutungsprophylaxe. Thieme, Stuttgart, p 205
Bozler G, Hammer R (1980) An international pharmacokinetic study on pirenzepine following a single oral dose. Scand J Gastroenterol 15 [Suppl 66]: 27–32
Hammer R, Bozler G, Zimmer A, Koss FW (1977) Pharmakokinetik und Metabolismus von L-S 519 CL2 (Pirenzepin) beim Menschen. Therapiewoche 27: 1575–1593
Tanswell P, Kasper W, Zahn G (1986) Automated monoclonal radioimmunoassays for pirenzepine, a selective muscarinic receptor antagonist, in plasma and urine. J Immunol Meth 93: 247–258
Heinzel G (1982) Curve fitting programs In: Bozler G, van Rossum SM (eds) Pharmacokinetics during drug development. Fischer, Stuttgart, p 207
Boxenbaum HG, Riegelman S, Elashoff RM (1974) Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 2: 123–48
Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6: 165–75
Ponte CD, Nappl JM (1981) Review of a new gastrointestinal drug-metoclopramide. Am J Hosp Pharm 1981: 829–833
Krakamp B, Tanswell P, Vogel H, Bozler G (1989) Steady state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction. Eur J Clin Pharmacol 36: 75–78
Krakamp B, Tanswell P, Leidig P, Vogel H, Schmitz R, Bozler G (1989) Steady state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal and hepatic insufficiency. Eur J Clin Pharmacol 36: 71–73
Londong W, Londong V, Federle C, Tanswell P, Voderholzer U (1989) Pharmacokinetic and pharmacodynamic studies in man stimulating acute and chronic treatment with oral pirenzepine. Eur J Clin Pharmacol 1989; 36: 369–74
Author information
Authors and Affiliations
Additional information
Dedicated to Professor Ellen Weber on the occasion of her 60th birthday
Rights and permissions
About this article
Cite this article
Tanswell, P., Hofgärtner, F., Bozler, G. et al. Absolute bioavailability of pirenzepine in intensive care patients. Eur J Clin Pharmacol 38, 265–268 (1990). https://doi.org/10.1007/BF00315028
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315028